On February 20, 2022, Kexing Biopharmaceutical Co., Ltd. (hereinafter referred to as Kexing Pharmaceuticals) issued an announcement that Shenzhen Kexing Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenzhen Kexing"), a wholly-owned subsidiary of Kexing Pharmaceuticals, would On February 18, Antaiwei signed the "SHEN26 Project Cooperation Agreement" (hereinafter referred to as the "Cooperation Agreement") with Shenzhen Antaiwei Biomedical Co., Ltd. (hereinafter referred to as "Antaiwei"). The intellectual property rights of SHEN26 are exclusively licensed to Shenzhen Kexing, and the subsequent research and development rights and commercialization rights of the products are transferred to Shenzhen Kexing.
The signing of this cooperation agreement will further accelerate the company's innovative drug layout, increase product reserves, enhance the company's core competitiveness, enrich the company's anti-viral product pipeline, and continuously improve the pharmaceutical research and development, production and sales systems, and promote the company's business continuity, rapidity and health. developing.
